R. Landman

发表

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

C. Fagard, Y. Yazdanpanah, B. Spire, 2018, The Journal of antimicrobial chemotherapy.

Comparative Selection of the K65R and M184V/I Mutations in Human Immunodeficiency Virus Type 1-Infected Patients Enrolled in a Trial of First-Line Triple-Nucleoside Analog Therapy (Tonus IMEA 021)

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2005, Journal of Virology.

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

D. Podzamczer, B. Clotet, A. Winston, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Variability of attitudes toward early initiation of HAART for HIV infection: A study of French prescribing physicians

J. Moatti, R. Landman, P. Huard, 2000, AIDS care.

Budget impact of antiretroviral therapy in a French clinic cohort

C. Charpentier, Y. Yazdanpanah, M. Préau, 2017, AIDS.

Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study

E. Delaporte, S. Bertout, H. Menan, 2019, PLoS neglected tropical diseases.

Two-Year Observational Study in Patients Infected with Drug-Resistant HIV-1 and Treated with the Fusion Inhibitor Enfuvirtide: The ZOOM Cohort

G. Chêne, P. Girard, J. Meynard, 2011 .

Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why?

V. Calvez, P. Muret, G. Peytavin, 2017, The Journal of antimicrobial chemotherapy.

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.

C. Charpentier, F. Brun-Vézinet, Y. Yazdanpanah, 2014, The Journal of antimicrobial chemotherapy.

Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.

J. Izopet, G. Chêne, S. Kolta, 2010, The Journal of antimicrobial chemotherapy.

HIV Infection and Long‐Term Residual Cardiovascular Risk After Acute Coronary Syndrome

G. Finet, F. Duclos, J. Trochu, 2020, Journal of the American Heart Association.

Antiretroviral therapy in resource-poor countries: illusions and realities.

M. Desvarieux, P. Girard, R. Landman, 2005, American journal of public health.

Evaluation of Four Tenofovir-Containing Regimens as First-Line Treatments in Cameroon and Senegal: The Anrs 12115 Dayana Trial

C. Charpentier, E. Delaporte, S. Eymard-Duvernay, 2014, Antiviral therapy.

Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study.

D. Minta, G. Peytavin, S. Eholie, 2019, The lancet. HIV.

PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA RELAPSE BY PENTAMIDINE AEROSOL IN ZIDOVUDINE-TREATED AIDS PATIENTS

R. Farinotti, C. Gaudebout, P. Girard, 1989, The Lancet.

HIV-1-RNA kinetics in blood plasma and in seminal plasma of men starting a dolutegravir-based triple-combination regimen at the time of primary HIV-1 infection.

C. Delaugerre, M. Lê, G. Peytavin, 2021, The Journal of infectious diseases.

Management of Late-presenting Patients with HIV Infection

J. Gatell, J. Rockstroh, A. Antinori, 2010, Antiviral therapy.

Impact of Adding Enfuvirtide to the Predictive Value of the Darunavir Genotypic Resistance Score

C. Charpentier, F. Brun-Vézinet, C. Katlama, 2011, Journal of acquired immune deficiency syndromes.

Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy.

C. Charpentier, E. Delaporte, S. Eymard-Duvernay, 2015, The Journal of antimicrobial chemotherapy.

Quality of life and depression among HIV‐infected patients receiving efavirenz‐ or protease inhibitor‐based therapy in Senegal

E. Delaporte, P. Sow, B. Ndiaye, 2007, HIV medicine.

Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE)

J. Durrieu, J. Montastruc, J. Chastang, 2022, Clinical Microbiology and Infection.

Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients

S. Mboup, F. Becher, M. Vray, 2004, AIDS.

Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.

C. Gaudebout, R. Olivares, P. Girard, 1993, The New England journal of medicine.

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal

E. Delaporte, S. Mboup, P. Sow, 2003, AIDS.

Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010.

V. Calvez, C. Charpentier, D. Descamps, 2013, The Journal of antimicrobial chemotherapy.

Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal

E. Delaporte, P. Sow, G. Peytavin, 2007, Journal of the International AIDS Society.

Early Virologic Failure and Rescue Therapy of Tenofovir, Abacavir, and Lamivudine for Initial Treatment of HIV-1 Infection: TONUS Study

C. Katlama, C. Michelet, G. Peytavin, 2005, HIV clinical trials.

Once-Daily Dosing of Saquinavir Soft-Gel Capsules and Ritonavir Combination in HIV-1-Infected Patients (Imea015 Study)

F. Brun-Vézinet, C. Michelet, R. Farinotti, 2003, Antiviral therapy.

Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.

F. Brun-Vézinet, C. Katlama, G. Peytavin, 2009, The Journal of antimicrobial chemotherapy.

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.

D. Podzamczer, J. Gatell, J. Mallolas, 2015, The Lancet. Infectious diseases.

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).

A. Samri, D. Costagliola, G. Peytavin, 2016, The Journal of antimicrobial chemotherapy.

Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case–control study

C. Charpentier, Y. Yazdanpanah, M. Lê, 2017, The Journal of antimicrobial chemotherapy.

HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens.

C. Rouzioux, D. Costagliola, B. Spire, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial

C. Katlama, M. Duracinsky, D. Costagliola, 2018, The Journal of antimicrobial chemotherapy.

Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2012, The Journal of antimicrobial chemotherapy.

Simplification and First Validation of a Short Battery of Patient Questionnaires for Clinical Management of HIV-Infected Patients: The HIV-SQUAD (Symptom Quality of life Adherence) Questionnaire®

B. Spire, B. Arnould, J. Gilquin, 2009, HIV clinical trials.

Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients.

E. Delaporte, P. Sow, J. Etard, 2008, AIDS research and human retroviruses.

A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.

C. Katlama, Y. Yazdanpanah, M. Duracinsky, 2022, The lancet. HIV.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Gag Mutations Can Impact Virological Response to Dual-Boosted Protease Inhibitor Combinations in Antiretroviral-Naïve HIV-Infected Patients

C. Charpentier, F. Brun-Vézinet, C. Katlama, 2010, Antimicrobial Agents and Chemotherapy.

Microelimination or not? The changing epidemiology of HIV-HCV coinfection in France 2012-2018.

C. Charpentier, R. Tubiana, C. Katlama, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Incidence of and risk factors for medical care interruption in people living with HIV in recent years

Y. Yazdanpanah, J. Parienti, R. Verdon, 2019, PloS one.

Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.

V. Calvez, R. Tubiana, L. Mandelbrot, 2015, Antiviral therapy.

“Real life” use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study

P. Frange, G. Peytavin, O. Launay, 2019, PloS one.

Pulmonary tolerance of prophylactic aerosolized pentamidine in human immunodeficiency virus-infected patients.

P. Girard, R. Landman, A. Leprêtre, 1991, Chest.

Multimorbidity in Elderly Subjects according to the year of diagnosis of HIV-Infection - A Cross-Sectional DATAIDS Cohort Study.

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Kaposi sarcoma among people living with HIV in the French DAT’AIDS cohort between 2010 and 2015

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients

F. Brun-Vézinet, P. Yeni, S. Matheron, 2009, AIDS.

Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).

E. Delaporte, A. Diouf, N. Gueye, 2010, AIDS research and human retroviruses.

Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen

C. Charpentier, F. Brun-Vézinet, G. Peytavin, 2011, AIDS.

HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.

V. Calvez, C. Charpentier, Y. Yazdanpanah, 2019, The Journal of antimicrobial chemotherapy.

Risk Factors Associated with Severe/Critical COVID-19 in People Living with HIV-1

Y. Yazdanpanah, R. Landman, J. Ghosn, 2022, International Journal of Infectious Diseases.

Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.

V. Calvez, C. Charpentier, C. Katlama, 2019, The Journal of antimicrobial chemotherapy.

Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapy–Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals

R. Tubiana, C. Katlama, O. Godin, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals

C. Charpentier, C. Delaugerre, J. Pawlotsky, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence of HIV infection and cost of medical follow-up for asymptomatic seropositive patients followed in general practice in France.

A. Valleron, F. Fagnani, R. Landman, 1991, Health policy.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.

V. Calvez, C. Charpentier, C. Katlama, 2021, The Journal of antimicrobial chemotherapy.

Tenofovir-Emtricitabine-Efavirenz in HIV-I-Infected Adults in Senegal: A 96-Week Pilot Trial in Treatment-Naive Patients

E. Delaporte, S. Mboup, B. Ndiaye, 2009, Journal of the International Association of Physicians in AIDS Care.

Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.

D. Podzamczer, B. Clotet, A. Winston, 2020, The Journal of antimicrobial chemotherapy.

Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance.

P. Morlat, D. Costagliola, J. Alvarez, 2023, The Journal of antimicrobial chemotherapy.

Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2020, The Journal of antimicrobial chemotherapy.

Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.

V. Calvez, C. Charpentier, C. Katlama, 2012, The Journal of antimicrobial chemotherapy.

Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy

P. Girard, R. Landman, F. Bouscarat, 1998, AIDS.

Frequency of cytokine-producing T cells in HIV-infected patients treated with stavudine, didanosine, and ritonavir.

M. Sinet, C. Gaudebout, F. Chau, 2000, AIDS research and human retroviruses.

Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.

C. Charpentier, F. Brun-Vézinet, Y. Yazdanpanah, 2012, The Journal of antimicrobial chemotherapy.

Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression

R. Breban, A. Samri, C. Katlama, 2017, The Journal of antimicrobial chemotherapy.

No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir

V. Calvez, C. Charpentier, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Predictive Value of Liver Enzymes and Inflammatory Biomarkers for the Severity of Liver Fibrosis Stage in HIV/HCV Co-Infected Patients

C. Charpentier, F. Brun-Vézinet, Y. Yazdanpanah, 2013, PloS one.

Pharmacological data of a successful 4‐days‐a‐week regimen in HIV antiretroviral therapy (ANRS 162‐4D trial)

C. Katlama, D. Costagliola, J. Alvarez, 2020, British journal of clinical pharmacology.

SARS-COV2 infection in 30 HIV-infected patients followed-up in a French University Hospital

Y. Yazdanpanah, V. Joly, S. Le Gac, 2020, International Journal of Infectious Diseases.

Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study.

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2020, The Journal of antimicrobial chemotherapy.

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

C. Katlama, Y. Yazdanpanah, C. Blanco-Betancourt, 2017, HIV medicine.

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV‐1 coreceptor tropism

V. Calvez, C. Charpentier, G. Carcelain, 2012, Journal of Medical Virology.

Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT’AIDS cohort

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2019, BMC Infectious Diseases.

No barrier to care, yet disparities in the HIV care continuum in France: a nationwide population study.

C. Katlama, Y. Yazdanpanah, E. Delaporte, 2021, Journal of Antimicrobial Chemotherapy.

Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection.

Y. Yazdanpanah, G. Peytavin, D. Descamps, 2021, The Journal of antimicrobial chemotherapy.

Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).

E. Delaporte, A. Diouf, N. Gueye, 2010, AIDS research and human retroviruses.

Gag Mutations Can Impact Virological Response to Dual-Boosted Protease Inhibitor Combinations in Antiretroviral-Naïve HIV-Infected Patients

R. Landman, G. Collin, A. Storto, 2010, Antimicrobial Agents and Chemotherapy.

Prevalence of and factors associated with depression among people living with HIV in France

F. Marion, M. Duracinsky, F. Lert, 2017, HIV medicine.

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV‐1 coreceptor tropism

V. Calvez, C. Charpentier, G. Carcelain, 2012, Journal of medical virology.

Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients

C. Cohen, M. de Béthune, D. Berger, 2009, AIDS.